Pansoral (Choline Salicylate, Cetalkonium Chloride)

Choline salicylate works by inhibiting cyclooxygenase enzymes, which reduces the production of prostaglandins—substances that mediate pain, fever, and inflammation. This action provides analgesic and anti‑inflammatory effects in oral tissues, while cetalkonium chloride disrupts bacterial cell membranes to provide antiseptic protection.

The dosage of Pansoral is determined by the prescribing healthcare professional based on the severity of the condition, patient age, and overall health. Patients should follow the specific instructions provided by their doctor or the product label and not exceed the recommended amount.

Safety of Pansoral in pregnancy or while breastfeeding has not been fully established. Women who are pregnant, planning to become pregnant, or nursing should consult their physician before using the product to weigh potential benefits against possible risks.

To order Pansoral, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Pansoral combines a salicylate NSAID with an antiseptic, offering both analgesic/anti‑inflammatory action and antimicrobial protection. Compared with standard oral NSAIDs that lack an antiseptic component, Pansoral may provide added benefit in conditions where bacterial colonisation contributes to discomfort, such as mouth ulcers or gingivitis.

Pansoral should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Pansoral is administered orally as a liquid solution. The recommended amount is usually measured with a calibrated dropper or spoon and held in the mouth for a short period before swallowing, allowing direct contact with the affected oral tissues.

Serious risks include allergic reactions such as rash, swelling, or anaphylaxis, and rare but significant gastrointestinal bleeding. Patients experiencing severe oral irritation, persistent ulceration, or systemic symptoms should discontinue use and seek medical attention promptly.

Individuals with known hypersensitivity to salicylates, cetalkonium chloride, or any component of the formulation should avoid Pansoral. It is also contraindicated for patients taking other oral NSAIDs, anticoagulants, or corticosteroids without medical supervision, and for children unless specifically directed by a healthcare professional.